復(fù)旦大學(xué)附屬中山醫(yī)院肝癌研究所樊嘉教授領(lǐng)銜的課題組在肝癌細(xì)胞、腫瘤微環(huán)境和肝癌轉(zhuǎn)移與復(fù)發(fā)領(lǐng)域又取得新進(jìn)展,，課題組發(fā)現(xiàn)人體內(nèi)一種微小蛋白質(zhì)——四跨膜蛋白CD151是肝癌侵襲轉(zhuǎn)移的關(guān)鍵因素,，四跨膜蛋白CD151與整合素α6β1高表達(dá)的肝癌細(xì)胞亞群在與腫瘤微環(huán)境的相互作用過(guò)程中可獲得高侵襲和轉(zhuǎn)移的能力，這將為肝癌抗復(fù)發(fā)和轉(zhuǎn)移治療提供新的思路和靶點(diǎn),。美國(guó)胃腸病學(xué)會(huì)會(huì)刊——著名的《胃腸病學(xué)》雜志 Gastroenterology于2月11日在線刊登了該成果,。 肝癌是影響人類健康最常見(jiàn)的惡性腫瘤之一,，手術(shù)切除仍是目前首選的治療方式，但術(shù)后的高復(fù)發(fā)和轉(zhuǎn)移率明顯影響患者的長(zhǎng)期生存,，因此,，探索肝癌侵襲和轉(zhuǎn)移分子機(jī)制對(duì)于改善肝癌患者的生存具有重要意義。 近來(lái),，腫瘤微環(huán)境即“土壤”在腫瘤的復(fù)發(fā)和轉(zhuǎn)移中的作用受到腫瘤學(xué)家們高度關(guān)注,。復(fù)旦大學(xué)附屬中山醫(yī)院肝外科主任、肝癌研究所常務(wù)副所長(zhǎng)樊嘉教授領(lǐng)銜的課題組,，多年前就開(kāi)始“腫瘤細(xì)胞,、腫瘤微環(huán)境與肝癌轉(zhuǎn)移復(fù)發(fā)”的研究，發(fā)現(xiàn)四跨膜蛋白CD151是肝癌侵襲轉(zhuǎn)移的關(guān)鍵因素,。 據(jù)樊嘉教授介紹,，CD151是四跨膜蛋白超家族重要成員之一，當(dāng)前已證實(shí)其在肝癌侵襲與轉(zhuǎn)移中扮演重要角色,，CD151的過(guò)度表達(dá)可促進(jìn)肝癌侵襲與轉(zhuǎn)移,。課題組多年潛心攻關(guān)，發(fā)現(xiàn)CD151和肝細(xì)胞生長(zhǎng)因子受體（c-Met）過(guò)度表達(dá)的患者,，其預(yù)后明顯差于僅c-Met過(guò)度表達(dá)的患者,，解釋了c-Met不能作為評(píng)價(jià)肝癌預(yù)后的獨(dú)立預(yù)測(cè)指標(biāo)的原因，提出了CD151作為判斷肝癌患者預(yù)后及抗復(fù)發(fā),、轉(zhuǎn)移治療靶點(diǎn)的優(yōu)勢(shì),。此成果于2009年刊發(fā)在《肝臟病》（Hepatology）上，并被《肝臟病》（Hepatology）,、《生物化學(xué)》（Journal of Biological Chemistry）等多個(gè)國(guó)際著名雜志引用,。課題組進(jìn)一步研究發(fā)現(xiàn)，CD151過(guò)度表達(dá)可促進(jìn)金屬基質(zhì)蛋白酶9（MMP9）的分泌和表達(dá),，參與肝癌新生血管形成、侵襲和轉(zhuǎn)移,；首次闡述了CD151過(guò)度表達(dá)在肝癌新生血管形成中的作用,，揭示了血管形成和肝癌轉(zhuǎn)移的新機(jī)制，此成果于2010年發(fā)表在《肝臟病》（Hepatology）上,。 該系列研究在“國(guó)家科技重大專項(xiàng)”,、國(guó)家“十一五”支撐計(jì)劃及國(guó)家自然科學(xué)基金等資助下，充分利用中山醫(yī)院肝癌研究所雄厚的基礎(chǔ)研究平臺(tái),、豐富而規(guī)范的臨床資源,，取得豐碩成果，研究觀點(diǎn)連續(xù)刊登在消化系統(tǒng)最權(quán)威的學(xué)術(shù)期刊《胃腸病學(xué)》（影響因子12.9）和《肝臟病》（影響因子10.8）雜志上,。不僅闡述了“種子”——肝癌細(xì)胞在腫瘤的發(fā)生和進(jìn)展中的地位,，還揭示了“種子”與“土壤”——腫瘤微環(huán)境如肝細(xì)胞生長(zhǎng)因子,、腫瘤血管及腫瘤基質(zhì)間有著“千絲萬(wàn)縷”的聯(lián)系，并在肝癌侵襲和轉(zhuǎn)移中共同起著重要作用,，這將推動(dòng)肝癌轉(zhuǎn)移防治策略的調(diào)整,，并為肝癌的治療提供潛在的靶標(biāo)。（生物谷Bioon.com） 生物谷推薦原文出處： Gastroenterology doi:10.1053/j.gastro.2011.02.008 CD151 Amplifies Signaling by Integrin α6β1 to PI3K and Induces the Epithelial–Mesenchymal Transition in HCC Cells Ai-Wu Ke1, 2, Guo-Ming Shi1, Jian Zhou1, 2, Xiao-Yong Huang1, Ying-Hong Shi1, Zhen-Bin Ding1, Xiao-Ying Wang1, Ranjan Prasad Devbhandari1 and Jia Fan1, 2, Abstract Background & Aims Overexpression of CD151 is associated with poor prognosis for hepatocellular carcinoma (HCC), yet its role in pathogenesis is not known. Methods We analyzed the expression of the integrin subunit α6 by quantitative, real-time PCR and immunoblot analyses of 120 HCC tissue samples; its clinical significance was investigated using tissue microarray (TMAs) analysis of samples from 335 patients with HCC. Immunoprecipitation was used to assess the relationship between α6 and CD151. The molecular effects of high expression levels of α6 and CD151 in HCC cells were determined using RNA interference and pharmacological approaches. Results Overexpression of α6 correlated with poor prognosis of patients with HCC; α6 formed a complex with endogenous CD151 in HCC cells. In cells that expressed high levels of α6 and CD151, laminin-5 (Ln-5) promoted cell spreading by inducing the epithelial–mesenchymal transition (EMT); this effect was not observed in cells that expressed high levels of only α6 or CD151. Cells that expressed high levels of α6 and CD151 underwent the EMT in response to Ln-5, through hyperactivation of phosphatidylinositol-3-kinase (PI3K), primarily induced via the PI3K–Akt–Snail–PTEN feedback pathway. The EMT was reversed by PI3K inhibitors and antibodies against CD151 or α6 in vitro, and was delayed by specific interference with CD151 and α6 in vivo. Conclusion High expression levels of CD151 and α6 promote invasiveness of HCC cells. Either of these proteins, or PI3K signaling, might be targets for therapeutics for subgroups of patients with HCC. Keywords: liver cancer, tumor progression, metastasis, tumor invasion